Table 3

Effect of FLM on α1- and β3-subunit antibody immunostaining in hippocampus after 1-week FZP treatment

GroupCA1CA3DG
SOSPSRSLSOSPSRMOLGRNPC
relative gray value
α1-Subunit
 CON-VEH31.7  ± 2.027.7  ± 2.125.7  ± 1.936.1  ± 2.922.6  ± 2.215.6  ± 2.423.0  ± 2.025.8  ± 1.519.6  ± 1.714.0  ± 1.2
 FZP-VEH27.4  ± 1.124.4  ± 1.023.2  ± 0.833.2  ± 1.121.2  ± 1.314.7  ± 1.121.2  ± 1.225.3  ± 1.117.7  ± 1.114.0  ± 1.3
 pvalue.04* .12.15.23.55.69.39.76.31.98
 CON-FLM32.3  ± 1.827.9  ± 1.726.6  ± 1.437.9  ± 1.324.4  ± 1.116.9  ± 0.924.4  ± 1.228.3  ± 1.620.0  ± 1.616.0  ± 1.0
 FZP-FLM29.6  ± 1.926.9  ± 1.725.1  ± 2.036.2  ± 2.224.0  ± 1.616.8  ± 1.322.9  ± 1.627.9  ± 1.519.2  ± 1.315.0  ± 1.2
 pvalue.33.71.54.49.85.92.44.87.71.49
CA1CA3DG
SOSPSRSLSOSPSRMOLGRNPC
relative gray value
β3-Subunit
 CON-VEH69.5  ± 1.959.8  ± 5.264.5  ± 1.260.6  ± 2.265.5  ± 2.151.3  ± 2.866.5  ± 2.264.4  ± 2.149.0  ± 2.156.5  ± 1.6
 FZP-VEH72.4  ± 0.958.3  ± 2.067.0  ± 1.363.2  ± 1.972.2  ± 1.853.1  ± 1.772.3  ± 1.967.9  ± 1.949.7  ± 1.760.2  ± 1.7
 pvalue.76.54.24.36.02* .55.05* .21.79.12
 CON-FLM70.1  ± 2.060.0  ± 2.266.2  ± 1.961.9  ± 1.972.6  ± 2.751.8  ± 2.170.6  ± 1.664.9  ± 5.250.8  ± 2.056.7  ± 2.1
 FZP-FLM71.5  ± 1.359.2  ± 1.866.4  ± 1.460.8  ± 2.070.2  ± 3.452.1  ± 2.269.7  ± 2.664.8  ± 2.250.1  ± 8.258.7  ± 2.0
 pvalue.82.76.92.65.57.90.76.96.82.47

  • Values are mean ± S.E. relative gray level.

  • FLM: i.p. injection of flumazenil; VEH: i.p. injection of flumazenil vehicle α1. CON-VEH, n = 5; FZP-VEH,n = 7; CON-FLM, n = 6; FZP-FLM,n = 6; β3, CON-VEH, n = 6; FZP-VEH, n = 8; CON-FLM, n = 7; FZP-FLM, n = 8.

  • ∗, significant difference (p ≤ .05) between 1-week FZP and saccharin-treated control (CON) groups.